We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
GenVec Announces Manufacturing Agreement for TNFerade™
News

GenVec Announces Manufacturing Agreement for TNFerade™

GenVec Announces Manufacturing Agreement for TNFerade™
News

GenVec Announces Manufacturing Agreement for TNFerade™

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "GenVec Announces Manufacturing Agreement for TNFerade™"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

GenVec, Inc. has announced that it has entered into a manufacturing development agreement with Cobra Biomanufacturing Plc for TNFerade™, GenVec’s lead product candidate.

The agreement will cover technology transfer, scale-up, and validation of the manufacturing process for TNFerade through cGMP consistency lots that will be produced at Cobra’s facility in Oxford, United Kingdom.

“GenVec selected Cobra based upon their expertise in viral manufacturing and the experience of key staff members with commercial biopharmaceutical products. Activities under this agreement will establish a clear path for the submission of the chemistry, manufacturing, and controls (CMC) portion of a biological license application for TNFerade as GenVec works towards the completion of our current Phase III clinical trial,” said Dr. Bryan Butman, GenVec’s Senior Vice President of Vector Operations.

“We are delighted to work with GenVec on this exciting project. TNFerade has demonstrated great potential for the treatment of pancreatic cancer,” added Simon Saxby, Cobra Biomanufacturing’s Chief Operating Officer. “This agreement will leverage Cobra’s significant experience manufacturing recombinant adenovirus under cGMP conditions.”

Advertisement